Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will contribute its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetics products towards "high-end and domestically produced" offerings, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and reduce development costs [2] - The establishment of the AI R&D company will focus on globally pioneering raw materials and product development, addressing unmet market needs and injecting momentum into the long-term growth of Four Seasons' medical aesthetics business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥與深原質藥聯合成立AI研發公司 探索開發AI驅動的新型醫美產品 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，為 推 動 人 工 智 慧 技 術（「AI」）在 醫 療 美 容（「醫 美」）產 品 研 發 領 域 的 深 度 應 用 與 產 業 化 落 地，本 集 團 已 與 深 原 質 藥 生 物 科 技（北 京）有 限 公 司（「深原質藥」）簽 署 框 架 協 議。雙 方 將 聯 合 成 立 由 本 集 團 主 導 的AI研 發 公 司，共 同 探 ...

Core Insights - The company has reported a significant growth in both its medical aesthetics and innovative pharmaceutical businesses, with multiple key products receiving approval for commercialization [1][4][10] - The total revenue for the first half of the year reached approximately 1.146 billion RMB, representing a year-on-year increase of about 20.7%, while the profit attributable to shareholders was approximately 103 million RMB, marking a successful turnaround from losses [2][4] - The company declared an interim cash dividend of 0.99 RMB per share, highlighting its strong return capability since its IPO in 2010, with a total of 33 dividends amounting to approximately 7.5 billion RMB by the end of 2024 [2] Innovative Pharmaceutical Business - The innovative pharmaceutical segment has seen explosive growth, with revenues from innovative drugs and other pharmaceuticals reaching 58.2 million RMB, a year-on-year increase of 96.6%, driven primarily by a surge in sales of diabetes medications [4][6] - The company has optimized its business structure, allowing for efficient conversion of research and development results into commercial success, with R&D expenses decreasing by 21.9% to 153 million RMB [6][4] - Key products such as the anti-tumor drug Pyrocilin and the proton pump inhibitor Annelaz sodium have been approved and are expected to contribute significantly to revenue growth [6][7] Medical Aesthetics Business - The medical aesthetics segment achieved revenues of approximately 580 million RMB, reflecting a year-on-year growth of 81.3%, supported by strategic partnerships and an upgraded marketing strategy [10][11] - The company has launched several self-developed products, making it the first in the industry to offer a comprehensive range of aesthetic solutions, which is expected to drive further revenue growth [10][11] - A robust marketing network has been established, covering over 6,800 medical aesthetic institutions, ensuring rapid product distribution and market penetration [11] Strategic Outlook - The company has demonstrated strong execution capabilities and strategic foresight in both the innovative pharmaceutical and medical aesthetics sectors, with a focus on long-term growth [13] - With a cash reserve of nearly 3.9 billion RMB, the company is well-positioned for continued innovation and market expansion [13] - The market is beginning to recognize the company's intrinsic value, as evidenced by a stock price increase of over 150% within the year, indicating a potential for valuation re-rating [13]

四环医药(00460)发布公告，公司现任执行董事陈燕玲女士将获委任为公司提名委员会委员，自2025年9 月1日起生效。 ...

智通财经APP讯，四环医药(00460)发布公告，公司现任执行董事陈燕玲女士将获委任为公司提名委员会 委员，自2025年9月1日起生效。 该信息由智通财经网提供 ...

格隆汇8月29日丨四环医药(00460.HK)发布公告，公司现任执行董事陈燕玲将获委任为提名委员会委 员，自2025年9月1日起生效。 ...

四環醫藥控股集團有限公司（「本公司」） ( 於百慕達註冊成立之有限公司 ) (股份代號:0460) 董事會於 2010 年 10 月 8 日採納 並於 2012 年 3 月 19 日、2019 年 3 月 18 日及 2025 年 8 月 29 日修訂之 提名委員會職權範圍 1 成立 本公司董事會（「董事會」）於 2010 年 10 月 8 日決議組成並成立提名委員會（「提名委 員會」）， 其職權、職責及具體職務載述如下。 2 成員 3 秘書 本公司其中一名聯席公司秘書（「公司秘書」）或其代名人須出任提名委員會秘書。 4 法定人數 處理事務的法定人數為兩（2）名成員，均須為獨立非執行董事。正式召開並有足夠法定 人數之提名委員會會議可行使提名委員會所獲賦予或可行使的全部或任何授權、權力及酌 情權。 - 1 - 2.1 提名委員會成員由董事會選任，人數不得少於三（3）名，大部分成員須為獨立非 執行董事，而至少一名成員為不同性別。 2.2 提名委員會主席由董事會委任，須為董事會主席或獨立非執行董事。倘提名委員會 主席及╱或委任代表缺席會議，餘下出席成員須選出當中一名主持會議。處理董事 會主席繼任事宜時，董事會主席不 ...

Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 董事名單與其角色和職能 四 環 醫 藥 控 股 集 團 有 限 公 司 董 事 會（「董事會」）成 員 載 列 如 下。 執 行 董 事： 車馮升醫生 （主 席） 郭維城醫生 （副 主 席 兼 行 政 總 裁） 張炯龍醫生 陳燕玲女士 繆瑰麗女士 香 港，二 零 二 五 年 八 月 二 十 九 日 獨 立 非 執 行 董 事： 曾華光先生 朱迅博士 王冠先生 董 事 會 設 立 四 個 委 員 會。下 表 提 供 各 董 事 會 成 員 在 各 委 員 會 中 所 擔 任 的 職 位， 自 二 零 二 五 年 九 月 一 日 起 生 效。 | | | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | 風險管理 | | --- | --- | --- | --- | --- | --- | --- | | 董 | 事 | | | | | 委員會 | | 車馮升 | | | | M | | | | 郭維城 | | | | | M | M | ...

緊 接 陳 女 士 上 述 委 任 後，提 名 委 員 會 將 繼 續 由 大 多 數 獨 立 非 執 行 董 事 所 組 成， 且 包 括 至 少 一 名 不 同 性 別 的 董 事。其 中，獨 立 非 執 行 董 事 三 名（即 曾 華 光 先 生、 朱 迅 博 士 及 王 冠 先 生），執 行 董 事 兩 名（即 郭 維 城 醫 生 及 陳 女 士）。董 事 會 相 信， 該 任 職 變 動 可 加 強 董 事 會 的 效 能 及 多 元 化，並 進 一 步 完 善 本 公 司 整 體 的 企 業 管 治 常 規。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 提名委員會組成之變動 四 環 醫 藥 控 股 集 團 有 限 公 ...